New Mexico Educational Retirement Board decreased its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.6% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 12,300 shares of the life sciences company’s stock after selling 200 shares during the period. New Mexico Educational Retirement Board’s holdings in Illumina were worth $3,821,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently modified their holdings of ILMN. Standard Life Aberdeen plc lifted its position in Illumina by 13.6% during the 3rd quarter. Standard Life Aberdeen plc now owns 39,255 shares of the life sciences company’s stock valued at $14,408,000 after purchasing an additional 4,709 shares during the period. Mutual Advisors LLC bought a new stake in shares of Illumina in the 3rd quarter valued at about $292,000. HPM Partners LLC increased its stake in shares of Illumina by 29.0% in the 3rd quarter. HPM Partners LLC now owns 2,913 shares of the life sciences company’s stock valued at $1,069,000 after acquiring an additional 654 shares during the last quarter. Laurel Wealth Advisors Inc. increased its stake in shares of Illumina by 72.7% in the 3rd quarter. Laurel Wealth Advisors Inc. now owns 2,506 shares of the life sciences company’s stock valued at $919,000 after acquiring an additional 1,055 shares during the last quarter. Finally, AQR Capital Management LLC increased its stake in shares of Illumina by 17.1% in the 3rd quarter. AQR Capital Management LLC now owns 222,355 shares of the life sciences company’s stock valued at $81,618,000 after acquiring an additional 32,470 shares during the last quarter. Institutional investors and hedge funds own 90.46% of the company’s stock.
A number of analysts have recently commented on ILMN shares. Morgan Stanley lowered their price target on Illumina from $320.00 to $288.00 and set an “equal weight” rating for the company in a research note on Monday, January 7th. BidaskClub raised Illumina from a “sell” rating to a “hold” rating in a research note on Wednesday, February 13th. Zacks Investment Research cut Illumina from a “buy” rating to a “hold” rating in a research note on Monday, December 31st. Deutsche Bank cut Illumina from a “buy” rating to a “hold” rating and set a $296.53 target price for the company. in a research note on Friday, January 25th. Finally, Bank of America reissued a “buy” rating and set a $355.00 target price on shares of Illumina in a research note on Wednesday, January 30th. Three analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $346.97.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, January 29th. The life sciences company reported $1.32 earnings per share for the quarter, missing the consensus estimate of $1.36 by ($0.04). The business had revenue of $867.00 million for the quarter, compared to the consensus estimate of $865.33 million. Illumina had a return on equity of 24.51% and a net margin of 24.79%. Illumina’s revenue was up 11.4% compared to the same quarter last year. During the same period in the prior year, the business earned $1.44 earnings per share. As a group, sell-side analysts expect that Illumina, Inc. will post 6.53 EPS for the current fiscal year.
In other news, Director Jay T. Flatley sold 3,300 shares of the firm’s stock in a transaction that occurred on Wednesday, January 23rd. The shares were sold at an average price of $303.53, for a total transaction of $1,001,649.00. Following the completion of the transaction, the director now directly owns 329,979 shares of the company’s stock, valued at approximately $100,158,525.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Charles Dadswell sold 124 shares of the firm’s stock in a transaction that occurred on Friday, February 1st. The stock was sold at an average price of $280.11, for a total transaction of $34,733.64. Following the transaction, the senior vice president now directly owns 6,879 shares of the company’s stock, valued at $1,926,876.69. The disclosure for this sale can be found here. Insiders have sold a total of 34,826 shares of company stock valued at $10,604,560 over the last ninety days. Company insiders own 0.54% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “New Mexico Educational Retirement Board Trims Position in Illumina, Inc. (ILMN)” was originally published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.themarketsdaily.com/2019/04/17/new-mexico-educational-retirement-board-trims-position-in-illumina-inc-ilmn.html.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Featured Article: When is a capital gain realized?
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.